Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis.

Bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, has the potential to slow or even halt disease progression in IPF. Indeed, the strong pre-clinical rationale and promising early phase clinical trial data have raised expectations.